Price point is a key factor for wider market adoption of Amgen’s Amjevita in the US
United States
Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty
Pliant Therapeutics' recent fundraise to boost its rare disease pipeline comes when experts predict a challenging public market.
Briumvi may struggle to make headway in crowded multiple sclerosis market
Study finds potential association between ROBO2 and anthracycline-related cardiomyopathy
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox